Clinical Trials Logo

Brain Cancer clinical trials

View clinical trials related to Brain Cancer.

Filter by:

NCT ID: NCT01246869 Terminated - Brain Cancer Clinical Trials

Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water

Start date: March 27, 2013
Phase: Phase 1
Study type: Interventional

Purpose of Study This exploratory clinical study will investigate FMISO (fluoromisonidazole) in patients with (1) newly diagnosed primary malignant brain tumors (WHO [World Health Organization] Grade III or IV glial-based tumors) who have not had a complete surgical resection and by contrast MRI (Magnetic resonance imaging) have residual tumor > 1.0 cm in diameter and will be receiving radiotherapy or (2) newly diagnosed brain metastasis (> 1.0 cm in diameter who will be receiving radiotherapy. The ability to accurately assess tumor hypoxia and accurately determine the amount/degree of tumor hypoxia could potentially change patient management once validated as tumor hypoxia is known to be associated with a poor prognosis [Eyler 2008].

NCT ID: NCT01205334 Terminated - Clinical trials for Glioblastoma Multiforme

Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme

COGLI
Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Patients have a type of brain cancer called glioblastoma multiforme. Because most GBMs come back after standard therapy, patients are being asked to volunteer to take part in a research study using special immune cells. They may have already thought about being in this study. Some patients with GBM show evidence of infection with a virus called Cytomegalovirus before the time of their diagnosis. CMV is found in the cancer cells of some patients with GBM, suggesting that it may play a role in causing the disease. The cancer cells infected by CMV are able to hide from the body's immune system and escape destruction. We want to see if special white blood cells, called T cells, that have been trained to recognize and kill special parts of CMV infected cells can survive in the blood and affect the tumor. We have used this sort of therapy to treat different types of cancer that are positive for other viruses and have had variable results. Some patients have had responses others did not. It is not possible for us to predict if this treatment will work for GBM. The purpose of this study is to find the largest safe dose of CMV-T cells, to learn what the side effects are, and to see whether this therapy might help patients with GBM.

NCT ID: NCT01113463 Terminated - Brain Cancer Clinical Trials

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.

NCT ID: NCT01110876 Terminated - Clinical trials for Glioblastoma Multiforme

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Start date: June 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas. Phase II Objectives: Primary: To determine the efficacy of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in patients with recurrent glioblastoma multiforme as progression free survival using a two arm adaptive randomization phase II trial design. Secondary: To determine the radiological response, progression free survival (PFS) at 6 months, overall survival and unexpected toxicity in the two treatment arms; and to obtain exploratory data regarding histone 3 and 4 acetylation, treatment related changes in the epidermal growth factor receptor (EGFR) pathway proteins, and changes in e-cadherin and vimentin expression (mRNA /protein) levels in tumor tissue and peripheral monocytes in a subset of surgical patients.

NCT ID: NCT01105702 Terminated - Brain Cancer Clinical Trials

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

Start date: May 2010
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.

NCT ID: NCT01065805 Terminated - Cancer Clinical Trials

A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

Start date: March 20, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images. Tumour growth rate is a useful indicator of tumour aggression and response to treatment. Imaging and measuring the cell growth with 18F-FLT may be useful in monitoring response to anticancer treatment.

NCT ID: NCT01058850 Terminated - Brain Cancer Clinical Trials

Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas

Start date: June 2011
Phase: Phase 1
Study type: Interventional

This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the EGFRvIII peptide vaccine after conventional radiation.

NCT ID: NCT01048060 Terminated - Cancer Clinical Trials

Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure

Start date: February 2002
Phase:
Study type: Observational

The purpose of this study is to collect bone marrow samples for experimental studies.

NCT ID: NCT01014767 Terminated - Brain Cancer Clinical Trials

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Start date: November 2009
Phase: Phase 3
Study type: Interventional

This is a "tissue banking and data review" research study that also has a "clinical" research part: - The goal of the tissue banking part of this study is to store tissue in a research tissue bank by the International Society for Pediatric Oncology (SIOP) at an international reference center for choroid plexus tumors. The tissue will be used in future research related to cancer. - The goal of the data review part of this study is to collect information from the medical records of patients with choroid plexus tumors, and to store the information in SIOP databases for use in future research related to cancer. - The goal of this clinical research study is to compare 4 chemotherapy treatments for choroid plexus tumors. The safety and level of effectiveness of these study treatments will be compared and studied. The study drugs include different combinations of etoposide, carboplatin, vincristine, cyclophosphamide, methotrexate, doxorubicin, cisplatin, dactinomycin, temozolomide, and irinotecan.

NCT ID: NCT00636805 Terminated - Brain Cancer Clinical Trials

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

Start date: May 2008
Phase: Phase 2
Study type: Interventional

1. Primary Objective: - To determine the efficacy and tolerability of palonosetron and dexamethasone in preventing acute CINV in brain tumor patients during the first 24 hours of receiving Irinotecan /Bevacizumab regimens. 2. Secondary Objective - To determine the safety and tolerability of palonosetron in brain tumor patients. - To determine the effects of glucocorticoid and anticonvulsants on the efficacy of palonosetron. - To determine the efficacy of palonosetron and dexamethasone in preventing delayed CINV in brain tumor patients during days 2-5. - To determine if patients receiving palonosetron have less fatigue than baseline.